Laurus Labs Limited (LAURUSLABS.BO)
INR 579.2
(3.34%)
INR 579.2
(3.34%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.01 Billion INR | 17.89% |
| 2022 | 18.79 Billion INR | 28.05% |
| 2021 | 14.67 Billion INR | 24.47% |
| 2020 | 11.79 Billion INR | 26.06% |
| 2019 | 9.35 Billion INR | 22.24% |
| 2018 | 7.65 Billion INR | 23.86% |
| 2017 | 6.17 Billion INR | 14.83% |
| 2016 | 5.37 Billion INR | 21.2% |
| 2015 | 4.43 Billion INR | 99.97% |
| 2014 | 2.21 Billion INR | 25.97% |
| 2013 | 1.76 Billion INR | 29.91% |
| 2012 | 1.35 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.12 Billion INR | -45.91% |
| 2024 Q2 | 6.04 Billion INR | 93.23% |
| 2023 Q3 | 5.66 Billion INR | 3.21% |
| 2023 FY | 22.15 Billion INR | 17.89% |
| 2023 Q2 | 5.48 Billion INR | 5.21% |
| 2023 Q1 | 5.21 Billion INR | 41.42% |
| 2023 Q4 | 5.78 Billion INR | 2.1% |
| 2022 Q3 | 5.06 Billion INR | 0.98% |
| 2022 Q1 | 5.02 Billion INR | 63.54% |
| 2022 Q4 | 3.68 Billion INR | -27.14% |
| 2022 FY | 18.79 Billion INR | 28.05% |
| 2022 Q2 | 5.01 Billion INR | -0.24% |
| 2021 Q4 | 3.07 Billion INR | -19.86% |
| 2021 Q2 | 3.88 Billion INR | 0.27% |
| 2021 Q3 | 3.83 Billion INR | -1.4% |
| 2021 FY | 14.67 Billion INR | 24.47% |
| 2021 Q1 | 3.87 Billion INR | 65.06% |
| 2020 Q2 | 3.14 Billion INR | 5.34% |
| 2020 Q3 | 3.3 Billion INR | 5.08% |
| 2020 Q4 | 2.34 Billion INR | -28.94% |
| 2020 FY | 11.79 Billion INR | 26.06% |
| 2020 Q1 | 2.98 Billion INR | 80.1% |
| 2019 Q4 | 1.65 Billion INR | -38.2% |
| 2019 Q1 | 2.38 Billion INR | 90.29% |
| 2019 Q2 | 2.62 Billion INR | 10.0% |
| 2019 Q3 | 2.68 Billion INR | 2.27% |
| 2019 FY | 9.35 Billion INR | 22.24% |
| 2018 Q1 | 2.01 Billion INR | 7.73% |
| 2018 FY | 7.65 Billion INR | 23.86% |
| 2018 Q4 | 1.25 Billion INR | -37.47% |
| 2018 Q3 | 2 Billion INR | -15.66% |
| 2018 Q2 | 2.37 Billion INR | 17.98% |
| 2017 Q3 | 1.76 Billion INR | 1.16% |
| 2017 Q4 | 1.87 Billion INR | 5.8% |
| 2017 FY | 6.17 Billion INR | 14.83% |
| 2017 Q1 | 1.65 Billion INR | 0.41% |
| 2017 Q2 | 1.74 Billion INR | 5.3% |
| 2016 Q1 | 1.36 Billion INR | 0.0% |
| 2016 Q4 | 1.65 Billion INR | 8.1% |
| 2016 FY | 5.37 Billion INR | 21.2% |
| 2016 Q3 | 1.52 Billion INR | 1.16% |
| 2016 Q2 | 1.51 Billion INR | 10.46% |
| 2015 FY | 4.43 Billion INR | 99.97% |
| 2014 FY | 2.21 Billion INR | 25.97% |
| 2013 FY | 1.76 Billion INR | 29.91% |
| 2012 FY | 1.35 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.028% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 92.326% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 74.136% |
| Granules India Limited | 7.18 Billion INR | 58.081% |
| Indoco Remedies Limited | 4.74 Billion INR | 36.598% |
| Achyut Healthcare Limited | 1.6 Million INR | -187022.436% |
| Ajanta Pharma Limited | 30.46 Billion INR | 90.116% |
| Alkem Laboratories Limited | 32.83 Billion INR | 90.831% |
| Alpa Laboratories Limited | 156.14 Million INR | -1828.183% |
| Brooks Laboratories Limited | 51.18 Million INR | -5782.767% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -15.782% |
| Bajaj HealthCare Limited | 985.34 Million INR | -205.558% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -112.144% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.86% |
| Eris Lifesciences Limited | 4.94 Billion INR | 39.089% |
| FDC Limited | 5.34 Billion INR | 43.708% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 95.544% |
| Gufic Biosciences Limited | 1.07 Billion INR | -179.37% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -41.739% |
| Ipca Laboratories Limited | 13.91 Billion INR | 78.363% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -289.289% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6423.096% |
| Lasa Supergenerics Limited | 291.17 Million INR | -934.021% |
| Lupin Limited | 95.67 Billion INR | 96.853% |
| Mankind Pharma Limited | 23.15 Billion INR | 86.996% |
| Medicamen Biotech Limited | 335.16 Million INR | -798.298% |
| Medico Remedies Limited | 161.84 Million INR | -1760.31% |
| Megasoft Limited | 49.52 Million INR | -5978.986% |
| NATCO Pharma Limited | 10.05 Billion INR | 70.066% |
| Piramal Pharma Limited | 19.91 Billion INR | 84.881% |
| RPG Life Sciences Limited | 1.63 Billion INR | -84.09% |
| Sigachi Industries Limited | 579.88 Million INR | -419.205% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.047% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -114.63% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -219.483% |
| Unichem Laboratories Limited | 6.72 Billion INR | 55.236% |
| Wanbury Limited | 1.16 Billion INR | -159.344% |
| Windlas Biotech Limited | 1 Billion INR | -199.133% |
| ZIM Laboratories Limited | 1.01 Billion INR | -197.199% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 93.026% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 2.145% |
| Divi's Laboratories Limited | 14.17 Billion INR | 78.752% |
| Hester Biosciences Limited | 908.84 Million INR | -231.279% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -0.514% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -173.961% |
| Bal Pharma Limited | 389.89 Million INR | -672.218% |
| Strides Pharma Science Limited | 9.16 Billion INR | 67.139% |
| Venus Remedies Limited | 1.91 Billion INR | -57.117% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 2.069% |
| Nectar Lifesciences Limited | 625.55 Million INR | -381.304% |
| Shilpa Medicare Limited | 2.18 Billion INR | -38.073% |
| Aarti Drugs Limited | 1.16 Billion INR | -157.889% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -174.008% |
| Suven Life Sciences Limited | 109.75 Million INR | -2643.326% |
| Ind-Swift Limited | 946.56 Million INR | -218.076% |
| Valiant Laboratories Limited | 36.28 Million INR | -8196.729% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 64.23% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 34.258% |
| Themis Medicare Limited | 782.85 Million INR | -284.592% |
| Hikal Limited | 2.48 Billion INR | -21.094% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 85.945% |
| Sequent Scientific Limited | 2.9 Billion INR | -3.756% |
| Novartis India Limited | 470.1 Million INR | -540.459% |
| Wockhardt Limited | 6.4 Billion INR | 52.956% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.17% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -18474.065% |
| Neuland Laboratories Limited | 2.92 Billion INR | -2.767% |
| Morepen Laboratories Limited | 1.98 Billion INR | -51.491% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -630.02% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -345.288% |